Table 2 Case reports of HCC treatment with SA monotherapy
Publication | Type of study | Number of enrolled patients and controls | Type of Cancer | SA used for treatment | Response to treatment-outcome | |
|---|---|---|---|---|---|---|
| Â | Â | Patients | Controls | Â | Â | Â |
Raderer 1999[207] | Case report | 1 | - | Advanced HCC | LAN SR (30 mg/10d) | ↓AFP, ↑TN, SD |
Siveke 2003[208] | Case report | 1 | - | Advanced HCC | OCT LAR (10 mg/28d) | CR, ↓AFP |
Deming 2005[209] | Case report | 1 | - | Metastatic HCC | OCT LAR (30 mg) | ↑QoL, ↓AFP, PR |
Borbath 2012[210] | Case report | 1 | - | Metastatic HCC with lung and mediastinal nodes, HBV+, | LAN SR (30Â mg/14d) | PR |